It did appreciate quite a lot in the run-up to results. That said, I see two way the results could have been better: (1) 12/12 patient improvement, and/or (2) full recovery of all 12 patients after 1 month...
Maybe, but I don't know the point of speculating about P3. If P2 full results are fantastic, this will be an immediate buyout candidate, although likely it would be a partnership deal to allow the CEO to collect more shares.
"In the meantime, do not commit any crimes for money to invest."
I guess that rules out working at Goldman Sachs. :-(
Note, there isn't any big material difference in the progress of ITEK's trials between today and July 22. The second phase 2 ended last year -- the first ending in 2012. The only difference is the the FDA allowed a placebo comparison in the Phase 3 trial (which I don't think even started yet), which will make the drug have an easier path to market... it is not worth 3 times more just because of that change, imo.
I think it is probably down due to hedge funds selling warrants and stops being triggered, which is my thesis for not buying yesterday... Gun to my head? I'd buy it at $.80, but it isn't.
Uhuh, and it is sort of good and bad. It seems like the stock is mainly controlled by a handful of greedy shorts and algos run amok... nothing that individual investors can normally do about it except to hunker down.